How Zimmer Biomet Is Driving Growth through Acquisitions
Zimmer Holdings acquired Biomet in 2015. Following the $14 billion merger, ZBH has deployed approximately $1.5 billion on eight M&A (merger and acquisition) deals.
Zimmer Biomet Holdings (ZBH) was trading at $123.3 as of April 24, 2017.
Wall Street analysts expect Zimmer Biomet’s 1Q17 revenue to be about $1.96 billion, a ~3% increase on a YoY (year-over-year) basis.
According to analyst estimates, Zimmer Biomet Holdings’ 1Q17 EPS (earnings per share) will come in at about $2.11.
Zimmer Biomet Holdings (ZBH) is set to release its 1Q17 results on April 27, 2017.
Baxter International (BAX) has exceeded analysts’ earnings estimates for the last few quarters.
On April 26, 2017, Baxter International (BAX) will announce its 1Q17 earnings.
Baxter International (BAX) is set to release its 1Q17 results on April 26, 2017.
Since 2012, Quest Diagnostics (DGX) has spent about $1.0 billion on capital investments and $1.0 billion on ten acquisitions to support inorganic growth.
Quest Diagnostics (DGX) expects to witness a 3.0%–5.0% long-term revenue growth rate in the future with earnings growth of 5.0%–9.0%.
Since 2012, Quest Diagnostics (DGX) has been working on a five-point strategy to boost revenue growth and improve quality, service, and efficiency.
With services offered to about half of the total hospitals, Quest Diagnostics (DGX) has become a leading provider of reference testing services in the United States.
Quest Diagnostics (DGX) has projected a run rate savings worth $1.3 billion by the end of 2017. In 2016, it managed to save up to $1.1 billion.
With around 50.0% of hospitals being served by Quest Diagnostics (DGX), the company has become a leading player in the fragmented US laboratory market.
Quest Diagnostics’ (DGX) expanding presence in the independent US laboratory market is worth $27.0 billion.
In 1Q17, Quest Diagnostics (DGX) had robust performances for all major financial metrics, including revenue, operating income, EPS, operating margins, and cash flow.
In its 1Q17 earnings transcript released on April 20, 2017, Quest Diagnostics (DGX) projected its 2017 revenues to fall $7.6 billion–$7.7 billion.
In a Reuters survey of 17 brokerage firms, ~64.7% of the analysts rated Intuitive Surgical a “buy,” and 29.4% rated it a “hold.”
Intuitive Surgical (ISRG) registered YoY (year-over-year) procedure growth of ~18% in 1Q17.
Intuitive Surgical’s share price rose more than 5% the day after the company released its 1Q17 earnings results.